ExoCoBio Inc.
A Top-Notch Exosome Therapy for Aged or Damaged Tissues

Albeit, exosomes were discovered more than 30 years ago, it was not until recently that it gained momentum amongst the scientific community for a range of its promising traits. Many scientific research bodies are exploring how exosomes can be leveraged as a bio-product in the bio-market field’s like liquid biopsy, precision medicine, and regenerative aesthetics.

One such company making great strides in applying ever-innovative exosome technologies to regenerative aesthetics is ExoCoBio Inc. based in South Korea which is the hot spot in global biotech industry. A renowned cosmeceutical & biopharmaceutical company, ExoCoBio is dedicated to develop products based on stem cell-derived exosomes for regenerative aesthetics and medicine. “By actively developing cosmeceuticals, regenerative medicine, and cosmetic medical devices, we believe that we could generate more benefits for people through our truly effective exosome-based products in the fields of regeneration, rejuvenation, anti-inflammation, and anti-aging,” says Byong S. Cho, Founder & CEO of ExoCoBio.

ExoCoBio has focused on the biggest advantage of exosomes, which is that it can be completely differentiated from other conventional regenerative ingredients. As a nano-sized particle covered by double lipid membranes coupled with active components like proteins, miRNAs, and others, exosomes can be successfully delivered into other cells without adverse side effects. ExoCoBio has developed a patented exosome isolation technology, ExoSCRT™, which assures high-purity, stability, safety, productivity, and even efficient exosome-based products to the market. With the development of ExoCoBio’s patented technology ExoSCRT™, the company has been honored to be nominated as the TOP 4 most funded exosome startups and as the only Asian company.

Adding to their innovation, the company has also developed ASCE+ SRLV-S, the cell-free cosmetics for skin rejuvenation, regeneration, and anti-inflammation based on exosome and ExoSCRT™ technology.

As a very first aesthetic product based on exosome, ASCE+ can benefit not only their clients but also the future development of the entire exosome industry. It’s an intensive formula delivering the concentrated power of over 5 billion stem cell-derived exosomes that can be absorbed quickly into the skin.

The Majority of ExoCoBio’s technologies have gained 6 patents for last 2 years, and their formulations are clinically proven to rejuvenate and regenerate the damaged skin. Aside from the regenerative area, ExoCoBio has also made discoveries in therapeutic areas. They have discovered that stem cell-derived exosomes that can alleviate atopic dermatitis and regenerate skin barrier, which was published in the journal of Stem Cell Research & Therapy (https://www.ncbi.nlm.nih. gov/pmc/articles/PMC6042362/). It contains 1,000+ proteins, growth factors, and cytokines which are helpful for overall skin regeneration, including maintenance skin barrier, anti-inflammation, anti-apoptosis, wound healing, skin elasticity, skin development, and cell proliferation as well. As stem cell-derived exosomes are believed to be a fundamental treatment for their potent anti-inflammatory effects, ExoCoBio keeps researching on them to develop a cure for atopic dermatitis, ulcerative colitis, and acute/chronic kidney injury. Exosome can be engineered to contain specific proteins or target particular tissues/cells. Thus, ExoCoBio believes that their engineered exosome material can be a potential treatment for cancer and other kinds of skin diseases in the near future.

Many meaningful cases show the efficacy of ExoCoBio’s stem cell-derived exosome products in healing severe and prolonged diseases. One such example is of their clinical trials, where one of their clients who had atopic dermatitis suffered from adverse side effects by using the steroid for many years. ExoCoBio tried to topically apply exosomes with iontophoresis for a few weeks into the lesion of the patient. After the treatment, the symptom of atopic dermatitis was significantly improved. The itchiness and red spots of the lesion were decreased immensely, and skin barriers became normal. Furthermore, this improvement was maintained for a few months without the usage of steroid or anti-histamine drug, which improved significantly the quality of life of the patient.

Giving an insight of the company’s future, Mr. Cho says, “For manufacturing stem cell-derived exosome in large scale, we are trying to set up our own chemistry, manufacturing, and control (CMC) process for standardization of the production.” They have been rapidly expanding all over the world, including US, Japan, Saudi Arabia, China, Russia, and others and their products have impressed numerous dermatologists, surgeons, and cosmetic professionals in more than 20 countries. Besides, they are looking forward to introducing the cutting-edge next-gen engineered exosomes technology in their portfolio, targeting specific domain to deliver reprogrammed therapeutic candidates.